Nab­bing late-stage drug, PTC ac­quires gene ther­a­py start­up Ag­ilis for $200M in cash/stock

Af­ter its bumpy road with a thrice-failed Duchenne drug, the team at PTC Ther­a­peu­tics has been busy putting new irons in its fire. In its lat­est ef­fort, the New Jer­sey com­pa­ny an­nounced Thurs­day that it’s ac­quir­ing a gene ther­a­py start­up with a few promis­ing drugs in its pipeline.

In­vestors, al­ready heart­ened by PTC’s new­ly-re­leased da­ta on a dif­fer­ent drug, are glow­ing. The com­pa­ny’s stock $PTCT has climbed 10% in af­ter-hours trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER